prostate cancer

A series of dice with a bag on them illustrating cost cuts
Biotech

Oric lays off 20% of workforce in focus on clinical-stage drugs

Oric’s plan to focus resources come with a sting in its tail—the biotech is laying off 20% of its employees to finance the strategy.
James Waldron Aug 13, 2025 6:20am
Paint brushes sitting on a colorful canvas

Radiopharma biotech Artbio paints path to clinic with $132M

Jul 29, 2025 7:30am
MA strategy deal block push come together form

Research non-profit acquires embattled Essa in Xoma-backed deal

Jul 14, 2025 9:30am
Micrograph showing the most common prostate cancer

Nuclidium raises $99M for copper-based radiopharma pipeline

Jul 10, 2025 5:04am
White arrow on a road pointing to the rising sun

J&J shares survival data on KLK2 bispecific in prostate cancer

Jun 2, 2025 6:40am
handshake deal shake hand arrows ok yes

Juri inks $210M T-cell engager deal with China biotech

May 27, 2025 6:00am